动脉输注吉西他滨治疗103例晚期肿瘤的疗效观察

目的：观察经动脉输注吉西他滨治疗晚期肿瘤的疗效。方法：103例经病理证实的晚期肿瘤患者，在病程的某个阶段，经动脉途经输注以吉西他滨为主的化疗药物及免疫增强剂IL-2。结果：68例胰腺癌患者中有29．4％获疼痛程度、止痛剂用药显著而持久的改善。受益反应持续时间为19．2周，中位生存期7．13个月：6个月、9个月、12个月的生存率分别为45．6％、23．5％、17．6％．1l例胆囊癌患者中有27．3％获疼痛程度、止痛剂用量的显著而持久的改善，临床受益反应持续时间为18．8周。中位生存期7．45个月；6个月、9个月、12个月的生存率分别为54．5％、27．3％、18．2％。8例非小细胞肺癌有效率达62．5％，1年生存率37．5％；6例肠癌有效率达83．3％，1年、2年生存率分别为66．7％、33．3％；7例肝癌有效率85．7％，1年、2年生存率分别为71．4％、42．9％。结论：经动脉输注吉西他滨能明显改善晚期肿瘤的生活质量，延长生存期。

Study of curative effect of infusion gemcitabine via artery for 103 cases with advanced cancer

Objective: To observe the efficacy of infusion gemcitabine via artery for advanced cancer. Methods:103 cases advanced cancer proved by pathology,received the chemotherapy combining gemciabine plus IL-2 infused into artery , in some stage of course. Results: In 68 pancreatic cancer,the obvious improvement in pain was 29.4%,the duration of clinical benefit responses was 19.2 weeks, the survival rate was 45.6%,23.5%,17.6%, with median survival of 7.13,6,9,12 months. In 11 gallbladder cancer, the obvious improvement in pain was 27.2%, the duration of CBR was 18.8 weeks, the survival rates was 54.5%,27.3%,18.2% with median survival of 7.45,6 ,9,12months. The response rate was 62.5% in 8 non-small cell lung cancer, 1 year survival rate was 37.5%.In 6 eolorectal cancer and 7 liver cancer,the response rates was 83.3% and 85.7% . 1,2 years survival rates was 66.7% , 33.3% and 71.4% , 42.9%. Conclusions: Infusion gemcitabine via artery can not only prolong survival rate but also improve life of quality.